Market Place
Sourcing Support
Antengene Presents Late-Stage Selinexor Results at ASH 2024
09 Dec 2024 //
PR NEWSWIRE
Karyopharm to Present Selinexor Data at ASH Annual Meeting
18 Nov 2024 //
PR NEWSWIRE
Orsini Now Provider for SAJAZIR Injection in Acute HAE Attacks
05 Nov 2024 //
PR NEWSWIRE
Antengene`s Xpovio® Approved For Third Indication In South Korea
17 Oct 2024 //
PR NEWSWIRE
Antengene To Commercialise XPOVIO In Thailand For Myeloma
23 Sep 2024 //
BIOSPECTRUM ASIA
Karyopharm Reports Q2 2024 Results And Recent Progress
06 Aug 2024 //
PR NEWSWIRE
Antengene Announces XPOVIO® (Selinexor) Approved in Malaysia
05 Aug 2024 //
PR NEWSWIRE
XPOVIO (Selinexor) Approved For DLBCL In China, Offering New Treatment Option
05 Jul 2024 //
PR NEWSWIRE
Antengene`s XPOVIO® Approved For Reimbursement In South Korea
26 Jun 2024 //
PR NEWSWIRE
Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO
13 Mar 2024 //
BUSINESSWIRE
Antengene Announces Inclusion of XPOVIO in National Reimbursement Drug List
14 Dec 2023 //
PR NEWSWIRE
Antengene Announces Inclusion of XPOVIO in 2023 China`s Drug List
13 Dec 2023 //
PR NEWSWIRE
Karyopharm Announces Clinical Trial Collaboration with BMS to Evaluate CC- 92480
30 Oct 2023 //
PR NEWSWIRE
Antengene, Hansoh Pharma enter partnership to commercialize Xpovio
12 Aug 2023 //
PHARMABIZ
Karyopharm cuts staff amid push to broaden use of blood cancer drug
03 Aug 2023 //
BIOPHARMADIVE
Karyopharm Initiates Pivotal Ph3 Study of XPO1 Inhibitor Selinexor & Ruxolitinib
28 Jun 2023 //
PR NEWSWIRE
Menarini Group Shares NEXPOVIO Subgroup Data from BOSTON trial
08 Jun 2023 //
PR NEWSWIRE
Antengene Announces XPOVIO plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS
31 May 2023 //
PR NEWSWIRE
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data
18 Apr 2023 //
PR NEWSWIRE
Karyopharm To Present Data from Phase 1 Study of Selinexor at AACR
14 Apr 2023 //
PR NEWSWIRE
MHRA Approves Selinexor Plus Bortezomib for Multiple Myeloma
22 Feb 2023 //
ONCLIVE
Karyopharm and Menarini Group Receive Full Marketing Authorization for NEXPOVIO
21 Feb 2023 //
PR NEWSWIRE
Foundation Medicine Announces Collaboration with Karyopharm for XPOVIO
10 Jan 2023 //
BUSINESSWIRE
Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data
05 Dec 2022 //
PRNEWSWIRE
Karyopharm Announces Selinexor Data in Myelofibrosis to be Presented at ASH
03 Nov 2022 //
PRNEWSWIRE
China-based startup Antengene accelerates expansion in APAC region
14 Sep 2022 //
BIOSPECTRUMASIA
Antengene Announces XPOVIO® Included for Reimbursement by the PBS in Australia
31 Aug 2022 //
PRNASIA
Researchers discover genes that predict good response to blood cancer therapy
15 Jun 2022 //
ECANCER
Antengene Begins Dosing in PI/II SWATCH Study of XPOVIO
22 May 2022 //
PRNEWSWIRE
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO in MM
20 May 2022 //
PRNEWSWIRE
Antengene Announces Commercial Availability of XPOVIO Across Mainland China
15 May 2022 //
PRNEWSWIRE
Karyopharm Announces XPOVIO Data to be Presented at the EHA 2022
12 May 2022 //
PRNEWSWIRE
Karyopharm Announces Selinexor Data to be Presented at the 2022 ASCO
27 Apr 2022 //
PRNEWSWIRE
TGA Approves Antengene`s XPOVIO for r/r and TCR Multiple Myeloma
09 Mar 2022 //
PRNEWSWIRE
Karyopharm Provides U.S. Regulatory Update on Selinexor
01 Mar 2022 //
PRESS RELEASE
Karyopharm plays ‘wild’ card with Xpovio in EC; pair of jacks or better?
09 Feb 2022 //
BIOWORLD
Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint
08 Feb 2022 //
PRNEWSWIRE
Karyopharm Reports Strong Q4 and FY 2021 Financial Results
08 Feb 2022 //
PRNEWSWIRE
Karyopharm and Menarini Group Enter into Exclusive License Agreement
21 Dec 2021 //
ASIAONE
Karyopharm, Menarini Enter Exclusive License Agreement to Commercialize NEXPOVIO
21 Dec 2021 //
PRNEWSWIRE
Antengene Shows Results of Phase 1b Trial of Selinexor in T & NK-Cell Lymphoma
13 Dec 2021 //
PRNEWSWIRE
Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study
18 Nov 2021 //
BUSINESSWIRE
Antengene Announces IND Approval in China for a Phase I/II Study of Selinexor
18 Nov 2021 //
ASIAONE
Antengene to Release Preliminary Results of Ph1b TOUCH of Selinexor (ATG-010)
09 Nov 2021 //
ANTENGENE
Antengene Granted IND Approval for Phase Ib of ATG-008+ATG-010 in rrDLBCL
01 Nov 2021 //
PRNEWSWIRE
Karyopharm Announces XPOVIO (selinexor) Data to be Presented at the EHA 2021
09 Jun 2021 //
PRNEWSWIRE
Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Strength Tablets
03 Jun 2021 //
KARYOPHARM
Karyopharm Announces European Medicines Agency`s Validation of its Type II
26 Apr 2021 //
PRESS RELEASE
Medivir has determined the starting dose for the next part phase Ib MIV-818
19 Apr 2021 //
PRNEWSWIRE
Karyopharm Announces Publication of Health-Related Quality of Life Outcomes
19 Apr 2021 //
PRESS RELEASE
Karyopharm Receives Conditional Marketing Authorization from European NEXPOVIO®
29 Mar 2021 //
PRNEWSWIRE
Antengene Announces NDA for ATG-010 Granted Priority Review by China`s
23 Feb 2021 //
PRNEWSWIRE
Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor)
29 Jan 2021 //
BIOSPACE
Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA
28 Jan 2021 //
PRNEWSWIRE
Antengene seeks South Korean MFDS approval for selinexor to treat rrMM
05 Jan 2021 //
PHARMABIZ
Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM
04 Jan 2021 //
PRNEWSWIRE
Antengene Submits NDA for ATG-010 in South Korea for rrMM and rrDLBCL
04 Jan 2021 //
BIOSPACE
FDA approves selinexor for refractory or relapsed multiple myeloma
21 Dec 2020 //
FDA
Antengene Announces Approval of IND App in China for a Ph3 Trial of ATG-010
18 Dec 2020 //
ANTENGENE
